Duvelisib’s original research company

Duvelisib (Duvelisib) is developed and produced by Verastem Oncology. Verastem Oncology is a biopharmaceutical company focused on developing and commercializing innovative anti-cancer therapeutics. The company's mission is to provide more treatment options for cancer patients, especially those with rare cancer types or limited treatment options. Duveliced u200bu200bis one of the important research results of Verastem Oncology. It belongs to a class of drugs called PI3K inhibitors and is used to treat specific types of lymphomas, such as adult T-cell leukemia lymphoma/lymphoma cell leukemia (ATLL/CTCL) and relapsed small B-cell lymphoma. These diseases are often related to abnormalities in the PI3K signaling pathway.